Chronic infection with hepatitis C virus (HCV) is a leading cause of advanced liver disease and hepatocellular carcinoma and a common indication for liver transplantation. The 2013-2015 EMA approvals of Gilead’s Sovaldi (sofosbuvir) and Harvoni (sofosbuvir/ledipasvir), combined with Bristol-Myers Squibb’s Daklinza (daclatasvir) and AbbVie’s Viekirax + Exviera (ombitasvir/paritaprevir/ritonavir + dasabuvir), have ushered in the era of interferon (IFN)-free direct-acting antiviral (DAA) therapy for chronic HCV infection and completely reshaped the HCV therapeutic market. The EMA’s recent authorization of Gilead’s Epclusa (sofosbuvir/velpatasvir) provides the first FDC approved for all HCV genotypes. Hepatitis C Virus | Access & Reimbursement | EU5 examines the market access factors that influence the success of IFN-free DAA therapies in the EU5 markets. The series is based on primary research with EU5 gastroenterologists and hepatologists, as well as country-specific payers. This research explores how payers and physicians interact and how reimbursement decisions influence the prescribing and uptake of specific therapies at the brand level.

Table of contents

  • Hepatitis C Virus - Access & Reimbursement - Detailed, Expanded Analysis (EU5)
    • Actionable Recommendations to Optimize Market Access
      • Optimizing Market Access Opportunity for New HCV Therapies in the EU5
    • Successes and Stumbles
      • Successes Among HCV Therapies in the EU5
      • Stumbles Among HCV Therapies in the EU5
      • France: Reimbursement Successes and Stumbles
        • Germany: Reimbursement Successes and Stumbles
          • Italy: Reimbursement Successes and Stumbles
            • Spain: Reimbursement Successes and Stumbles
              • United Kingdom: Reimbursement Successes and Stumbles
              • Key Stakeholders in the Road to Market Access
                • France
                • Germany
                • Italy
                • Spain
                • United Kingdom
              • Key Market Access Roadblocks
                • France: Key Market Access Roadblocks
                • Germany: Key Market Access Roadblocks
                • Italy: Key Market Access Roadblocks
                • Spain: Key Market Access Roadblocks
                • United Kingdom: Key Market Access Roadblocks
              • Reimbursement Dynamics
                • France
                  • France: Crucial HTA Criteria
                  • France: P&R Drivers and Key HTA Considerations
                  • France: P&R Drivers and Key HTA Considerations
                  • France: HTA Review Details for HCV Therapies
                  • France: Lessons Learned and Key Takeaways
                  • France: Key Background Details of the Healthcare System
                  • France: P&R Process
                  • France: P&R Process
                  • France: Reimbursement Details and Mechanisms
                  • France: Prescribing Restrictions, Dispensations, and Monitoring
                • Germany
                  • Germany: Crucial HTA Criteria
                  • Germany: P&R Drivers and Key HTA Considerations
                  • Germany: P&R Drivers and Key HTA Considerations
                  • Germany: HTA Review Details for Key HCV Therapies
                  • Germany: Lessons Learned and Key Takeaways
                  • Germany: Key Background Details of the Healthcare System
                  • Germany: P&R Process
                  • Germany: P&R Process
                  • Germany: Reimbursement Details and Mechanisms
                  • Germany: Prescribing Controls and Monitoring
                • Italy
                  • Italy: Crucial HTA Criteria
                  • Italy: P&R Drivers and Key HTA Considerations
                  • Italy: P&R Drivers and Key HTA Considerations
                  • Italy: HTA Review Details for Key HCV Therapies
                  • Italy: Lessons Learned and Key Takeaways
                  • Italy: Key Background Details of the Healthcare System
                  • Italy: P&R Process
                  • Italy: P&R Process
                  • Italy: Reimbursement Details and Mechanisms
                  • Italy: Prescribing Restrictions, Dispensations, and Monitoring
                • Spain
                  • Spain: Crucial HTA Criteria
                  • Spain: P&R Drivers and Key HTA Considerations
                  • Spain: P&R Drivers and Key HTA Considerations
                  • Spain: HTA Review Details for Key HCV Therapies
                  • Spain: Lessons Learned and Key Takeaways
                  • Spain: Key Background Details of the Healthcare System
                  • Spain: P&R Process
                  • Spain: P&R Process
                  • Spain: Reimbursement Details and Mechanisms
                • United Kingdom
                  • United Kingdom: Crucial HTA Criteria
                  • United Kingdom: P&R Drivers and Key HTA Considerations
                  • United Kingdom: P&R Drivers and Key HTA Considerations
                  • United Kingdom: HTA Review Details for Key HCV Therapies
                  • United Kingdom: Lessons Learned and Key Takeaways
                  • United Kingdom: Key Background Details of the Healthcare System
                  • United Kingdom: P&R Process
                  • United Kingdom: P&R Process
                  • United Kingdom: Reimbursement Details and Budget Controls
                  • United Kingdom: Prescribing Controls and Monitoring
              • Pricing and Reimbursement, Policy, and Coverage: Impact on Prescribing
                • Prescriber Preferences for Genotype 1 Patients
                  • Preferred Regimen for Treatment-Naive Non-Cirrhotic Genotype 1 Patients
                  • Preferred Regimen for Treatment-Naive Cirrhotic Genotype 1 Patients
                  • Preferred Regimen For Treatment-Experienced Non-Cirrhotic Genotype 1 Patients
                  • Preferred Regimen for Treatment-Experienced Cirrhotic Genotype 1 Patients
                • Prescriber Preferences for Genotype 2 Patients
                  • Preferred Regimen for Treatment-Naive Non-Cirrhotic Genotype 2 Patients
                  • Preferred Regimen for Treatment-Naive Cirrhotic Genotype 2 Patients
                  • Preferred Regimen for Treatment-Experienced Non-Cirrhotic Genotype 2 Patients
                  • Preferred Regimen for Treatment-Experienced Cirrhotic Genotype 2 Patients
                • Prescriber Preferences for Genotype 3 Patients
                  • Preferred Regimen for Treatment-Naive Non-Cirrhotic Genotype 3 Patients
                  • Preferred Regimen for Treatment-Naive Cirrhotic Genotype 3 Patients
                  • Preferred Regimen for Treatment-Experienced Non-Cirrhotic Genotype 3 Patients
                  • Preferred Regimen for Treatment-Experienced Cirrhotic Genotype 3 Patients
                • Impact of Payer Policy on Prescribing of HCV Therapies
                  • Reasons for Treatment Deferral, by HCV Genotype: EU5
                  • HCV Patients Who Were Not Prescribed Sovaldi due to Market Access Issues
                  • HCV Patients Who Were Not Prescribed Daklinza due to Market Access Issues
                  • HCV Patients Who Were Not Prescribed Harvoni due to Market Access Issues
                  • HCV Patients Who Were Not Prescribed Viekirax + Exviera due to Market Access Issues
                  • Market Access Issues That Affect Prescribing, by HCV Therapy: EU5
                  • HCV Subpopulations Most Affected by Market Access Issues: EU5
                • Top Prescribing Drivers of Key HCV Regimens
                  • Preferred Key Regimens for Genotype 1, by Clinical and Nonclinical Factors: EU5
                  • Reasons for Prescribing Sovaldi + RBV to Genotype 2 Patients, by Liver Disease Stage and Treatment Experience
                  • Preferred Key Regimens for Genotype 3, by Clinical and Nonclinical Factors: EU5
              • Market Access Landscape for Emerging Therapies
                • Likely Impact of Emerging Therapies on HCV Treatment Practices
                  • Current and Anticipated Patient Share for Treatment-Naive Non-Cirrhotic Genotype 1 Patients
                  • Anticipated Prescribing of Sofosbuvir/Velpatasvir +/- RBV vs. Most Prescribed Current Regimen in Treatment-Naive Non-Cirrhotic Genotype 2 Patients
                  • Current and Anticipated Patient Share for Treatment-Naive Non-Cirrhotic Genotype 3 Patients
                • Market Access Challenges for Emerging Therapies for HCV
                  • Current and Anticipated Cost-Containment Measures Used: EU5
                  • Current and Anticipated Involvement of Fibrosis Restrictions in Market Access, by HCV Therapy: EU5
                  • HCV Drug Development Priorities That Physicians View as Important to Payers: EU5
                  • Factors Influencing Selection of New HCV Therapies: EU5
                  • Reasons Why Zepatier +/- RBV Will Not Displace Any Currently Available HCV Regimen: EU5
                  • Reasons Why Sofosbuvir/Velpatasvir +/- RBV Will Not Displace Any Currently Available HCV Regimen: EU5
                  • EU5 Physician Opinion on Zepatier and Sofosbuvir/Velpatasvir Pricing Scenarios Required to Obtain Favorable Formulary Status
                • Payer Opinion on Emerging Therapies for HCV
                  • France: Payer Opinion on Emerging Therapies for HCV
                  • Germany: Payer Opinion on Emerging Therapies for HCV
                  • Germany: Payer Opinion on Emerging Therapies for HCV
                  • Italy: Payer Opinion of Emerging Therapies for HCV
                  • Italy: Payer Opinion of Emerging Therapies for HCV
                  • Spain: Payer Opinion of Emerging Therapies for HCV
                  • Spain: Payer Opinion of Emerging Therapies for HCV
                  • United Kingdom: Payer Opinion of Emerging Therapies for HCV
                  • United Kingdom: Payer Opinion of Emerging Therapies for HCV
              • Methodology
                • Primary Research Design
                • Background of Payers and Payer-Advising KOLs
                • Physician Demographics and Practice Setting
                  • Physician Specialties
                  • Years in Practice Postresidency
                  • Country Practice Location
                  • Practice Location Within Community
                  • Average Number of HCV Patients Currently Being Managed
                  • Average Number of HCV Patients Treated
                  • Treatment Rates of HCV Patients Split by Genotype and Liver Damage: All Physicians
                  • Treatment Rates of HCV Patients Split by Genotype and Liver Damage: Gastroenterologists
                  • Treatment Rates of HCV Patients Split by Genotype and Liver Damage: Hepatologists
                  • Awareness of Current and Emerging HCV Therapies: Hepatologists
                  • Awareness of Current and Emerging HCV Therapies: All Physicians
                  • Awareness of Current and Emerging HCV Therapies: Gastroenterologists
                  • Ability to Prescribe HCV Therapies
                  • Prescribing of HCV Therapies Within the Past Six Months: All Physicians
                  • Prescribing of HCV Therapies Within the Past Six Months: Gastroenterologists
                  • Prescribing of HCV Therapies Within the Past Six Months: Hepatologists
                • Patient Characteristics
                  • Genotypic Makeup of HCV Patients Managed: All Physicians
                  • Genotypic Makeup of HCV Patients Managed: Gastroenterologists
                  • Genotypic Makeup of HCV Patients Managed: Hepatologists
                  • Liver Damage in HCV Patients: All Physicians
                  • Liver Damage in HCV Patients: Gastroenterologists
                  • Liver Damage in HCV Patients: Hepatologists
                  • HCV Patients with Previous Treatment Experience: All Physicians
                  • HCV Patients with Previous Treatment Experience: Gastroenterologists
                  • HCV Patients with Previous Treatment Experience: Hepatologists
                • Pricing Methodology
                  • Estimated Price of 12-Week Regimens of HCV Therapies
                  • General Statements About EU5 Pricing
                  • EU5 Sources for 2015 Drug Prices
                  • 2015 Exchange Rates
                  • Dosing Assumptions for Key HCV Therapies
              • Appendix
                • Key Current and Emerging Therapies for HCV
                  • Profiles of Key Current Therapies for HCV
                  • Profiles of Key Emerging Therapies for HCV
                  • Key Takeaways and Likely Impact of Emerging Therapies
                • Physician Survey Data
                  • Reasons for Treatment Deferral, by HCV Genotype: France
                  • Reasons for Treatment Deferral, by HCV Genotype: Germany
                  • Reasons for Treatment Deferral, by HCV Genotype: Italy
                  • Reasons for Treatment Deferral, by HCV Genotype: Spain
                  • Reasons for Treatment Deferral, by HCV Genotype: United Kingdom
                  • Reasons for Treatment Deferral, by HCV Genotype: EU5
                  • Treatment Approach in Non-Cirrhotic and Cirrhotic Genotype 1 HCV Patients
                  • Treatment Approach in Non-Cirrhotic and Cirrhotic Genotype 2 HCV Patients
                  • Treatment Approach in Non-Cirrhotic and Cirrhotic Genotype 3 HCV Patients
                  • Current Patient Share for Treatment-Naive Non-Cirrhotic Genotype 1 Patients
                  • Current Patient Share for Treatment-Naive Cirrhotic Genotype 1 Patients
                  • Current Patient Share for Treatment-Experienced Non-Cirrhotic Genotype 1 Patients
                  • Current Patient Share for Treatment-Experienced Cirrhotic Genotype 1 Patients
                  • Current Patient Share For Treatment-Naive Non-Cirrhotic Genotype 2 Patients
                  • Current Patient Share For Treatment-Naive Cirrhotic Genotype 2 Patients
                  • Current Patient Share For Treatment-Experienced Non-Cirrhotic Genotype 2 Patients
                  • Current Patient Share For Treatment-Experienced Cirrhotic Genotype 2 Patients
                  • Current Patient Share for Treatment-Naive Non-Cirrhotic Genotype 3 Patients
                  • Current Patient Share for Treatment-Naive Cirrhotic Genotype 3 Patients
                  • Current Patient Share for Treatment-Experienced Non-Cirrhotic Genotype 3 Patients
                  • Current Patient Share for Treatment-Experienced Cirrhotic Genotype 3 Patients
                  • Preferred Regimen for Treatment-Naive Non-Cirrhotic Genotype 1 Patients
                  • Preferred Regimen for Treatment-Naive Cirrhotic Genotype 1 Patients
                  • Preferred Regimen For Treatment-Experienced Non-Cirrhotic Genotype 1 Patients
                  • Preferred Regimen for Treatment-Experienced Cirrhotic Genotype 1 Patients
                  • Preferred Regimen for Treatment-Naive Non-Cirrhotic Genotype 2 Patients
                  • Preferred Regimen for Treatment-Naive Cirrhotic Genotype 2 Patients
                  • Preferred Regimen for Treatment-Experienced Non-Cirrhotic Genotype 2 Patients
                  • Preferred Regimen for Treatment-Experienced Cirrhotic Genotype 2 Patients
                  • Preferred Regimen for Treatment-Naive Non-Cirrhotic Genotype 3 Patients
                  • Preferred Regimen for Treatment-Naive Cirrhotic Genotype 3 Patients
                  • Preferred Regimen for Treatment-Experienced Non-Cirrhotic Genotype 3 Patients
                  • Preferred Regimen for Treatment-Experienced Cirrhotic Genotype 3 Patients
                  • Preferred Key Regimens for Genotype 1, by Clinical and Nonclinical Factors: EU5
                  • Preferred Key Regimens for Genotype 1, by Clinical and Nonclinical Factors: France
                  • Preferred Key Regimens for Genotype 1, by Clinical and Nonclinical Factors: Germany
                  • Preferred Key Regimens for Genotype 1, by Clinical and Nonclinical Factors: Italy
                  • Preferred Key Regimens for Genotype 1, by Clinical and Nonclinical Factors: Spain
                  • Preferred Key Regimens for Genotype 1, by Clinical and Nonclinical Factors: United Kingdom
                  • Preferred Key Regimens for Genotype 3, by Clinical and Nonclinical Factors: EU5
                  • Preferred Key Regimens for Genotype 3, by Clinical and Nonclinical Factors: France
                  • Preferred Key Regimens for Genotype 3, by Clinical and Nonclinical Factors: Germany
                  • Preferred Key Regimens for Genotype 3, by Clinical and Nonclinical Factors: Italy
                  • Preferred Key Regimens for Genotype 3, by Clinical and Nonclinical Factors: Spain
                  • Preferred Key Regimens for Genotype 3, by Clinical and Nonclinical Factors: United Kingdom
                  • Reasons for Prescribing Peg-IFN + RBV to Genotype 1 Patients, by Liver Disease Stage and Treatment Experience
                  • Reasons for Prescribing Victrelis/Incivo + Peg-IFN + RBV to Genotype 1 Patients, by Liver Disease Stage and Treatment Experience
                  • Reasons for Prescribing Olysio + Peg-IFN + RBV to Genotype 1 Patients, by Liver Disease Stage and Treatment Experience
                  • Reasons for Prescribing Daklinza + Peg-IFN + RBV to Genotype 1 Patients, by Liver Disease Stage and Treatment Experience
                  • Reasons for Prescribing Sovaldi + Olysio +/- RBV to Genotype 1 Patients, by Liver Disease Stage and Treatment Experience
                  • Reasons for Prescribing Sovaldi + RBV to Genotype 1 Patients, by Liver Disease Stage and Treatment Experience
                  • Reasons for Prescribing Sovaldi + Peg-IFN + RBV to Genotype 1 Patients, by Liver Disease Stage and Treatment Experience
                  • Reasons for Prescribing Harvoni +/- RBV to Genotype 1 Patients, by Liver Disease Stage and Treatment Experience
                  • Reasons for Prescribing Viekirax + Exviera +/- RBV to Genotype 1 Patients, by Liver Disease Stage and Treatment Experience
                  • Reasons for Prescribing Sovaldi + Daklinza +/- RBV to Genotype 1 Patients, by Liver Disease Stage and Treatment Experience
                  • Reasons for Prescribing Peg-IFN + RBV to Genotype 2 Patients, by Liver Disease Stage and Treatment Experience
                  • Reasons for Prescribing Sovaldi + Peg-IFN + RBV to Genotype 2 Patients, by Liver Disease Stage and Treatment Experience
                  • Reasons for Prescribing Sovaldi + RBV to Genotype 2 Patients, by Liver Disease Stage and Treatment Experience
                  • Reasons for Prescribing Harvoni +/- RBV to Genotype 2 Patients, by Liver Disease Stage and Treatment Experience
                  • Reasons for Prescribing Sovaldi + Daklinza +/- RBV to Genotype 2 Patients, by Liver Disease Stage and Treatment Experience
                  • Reasons for Prescribing Peg-IFN + RBV to Genotype 3 Patients, by Liver Disease Stage and Treatment Experience
                  • Reasons for Prescribing Sovaldi + RBV to Genotype 3 Patients, by Liver Disease Stage and Treatment Experience
                  • Reasons for Prescribing Sovaldi + Peg-IFN + RBV to Genotype 3 Patients, by Liver Disease Stage and Treatment Experience
                  • Reasons for Prescribing Harvoni +/- RBV to Genotype 3 Patients, by Liver Disease Stage and Treatment Experience
                  • Reasons for Prescribing Sovaldi + Daklinza +/- RBV to Genotype 3 Patients, by Liver Disease Stage and Treatment Experience
                  • Current and Anticipated Cost-Containment Measures Used: EU5
                  • Current and Anticipated Cost-Containment Measures: France
                  • Current and Anticipated Cost-Containment Measures: Germany
                  • Current and Anticipated Cost-Containment Measures: Italy
                  • Current and Anticipated Cost-Containment Measures: Spain
                  • Current and Anticipated Cost-Containment Measures: United Kingdom
                  • HCV Subpopulations Most Impacted by Market Access Issues: France
                  • HCV Subpopulations Most Impacted by Market Access Issues: Germany
                  • HCV Subpopulations Most Impacted by Market Access Issues: Italy
                  • HCV Subpopulations Most Impacted by Market Access Issues: Spain
                  • HCV Subpopulations Most Impacted by Market Access Issues: United Kingdom
                  • HCV Subpopulations Most Affected by Market Access Issues: EU5
                  • HCV Patients Who Were Not Prescribed the Preferred Regimen due to Market Access Issues
                  • HCV Patients Who Were Not Prescribed Sovaldi due to Market Access Issues
                  • HCV Patients Who Were Not Prescribed Harvoni due to Market Access Issues
                  • HCV Patients Who Were Not Prescribed Viekirax + Exviera due to Market Access Issues
                  • HCV Patients Who Were Not Prescribed Daklinza due to Market Access Issues
                  • HCV Patients Who Were Not Prescribed Victrelis due to Market Access Issues
                  • HCV Patients Who Were Not Prescribed Incivo due to Market Access Issues
                  • HCV Patients Who Were Not Prescribed Olysio due to Market Access Issues
                  • Market Access Issues That Affect Prescribing, by HCV Therapy: EU5
                  • Market Access Issues That Affect Prescribing, by HCV Therapy: France
                  • Market Access Issues That Affect Prescribing, by HCV Therapy: Germany
                  • Market Access Issues That Affect Prescribing, by HCV Therapy: Italy
                  • Market Access Issues That Affect Prescribing, by HCV Therapy: Spain
                  • Market Access Issues That Affect Prescribing, by HCV Therapy: United Kingdom
                  • Current and Anticipated Involvement of Fibrosis Restrictions in Market Access, by HCV Therapy: EU5
                  • Current and Anticipated Involvement of Fibrosis Restrictions in Market Access, by HCV Therapy: France
                  • Current and Anticipated Involvement of Fibrosis Restrictions in Market Access, by HCV Therapy: Germany
                  • Current and Anticipated Involvement of Fibrosis Restrictions in Market Access, by HCV Therapy: Italy
                  • Current and Anticipated Involvement of Fibrosis Restrictions in Market Access, by HCV Therapy: Spain
                  • Current and Anticipated Involvement of Fibrosis Restrictions in Market Access, by HCV Therapy: United Kingdom
                  • Impact of EMA Label Recommendations and Regional/Local Eligibility Criteria, by HCV Therapy: France
                  • Impact of EMA Label Recommendations and Regional/Local Eligibility Criteria, by HCV Therapy: Germany
                  • Impact of EMA Label Recommendations and Regional/Local Eligibility Criteria, by HCV Therapy: Italy
                  • Impact of EMA Label Recommendations and Regional/Local Eligibility Criteria, by HCV Therapy: Spain
                  • Impact of EMA Label Recommendations and Regional/Local Eligibility Criteria, by HCV Therapy: United Kingdom
                  • Impact of EMA Label Recommendations and Regional/Local Eligibility Criteria, by HCV Therapy: EU5
                  • Changes to Budgeting for HCV Therapies, 2014-2016
                  • Changes in Ability to Prescribe Preferred HCV Therapy
                  • Relevance of ALD Status in France, by HCV Therapy
                  • Relevance of ALD Status in France with Respect to Coverage of HCV-Related Medical Costs
                  • Changes to Number of HCV Patients Seeking ALD Status in France
                  • Impact of Richtgrosen on HCV Therapy Prescribing in Germany
                  • Impact of G-BA Decisions on HCV Therapy Prescribing in Germany
                  • Relevance of Reimbursement/Budgetary Issues and RNRL Designation in Italy, by HCV Therapy
                  • Regional/Local Control over Prescribing in Italy, by HCV Therapy
                  • Impact of AEMPS or GENESIS/Regional Decisions on Prescribing in Spain
                  • Impact of Recent NICE Recommendations for Key HCV Therapies on Prescribing in the United Kingdom
                  • HCV Drug Development Priorities Important to Physicians: EU5
                  • HCV Drug Development Priorities Important to Physicians: France
                  • HCV Drug Development Priorities Important to Physicians: Germany
                  • HCV Drug Development Priorities Important to Physicians: Italy
                  • HCV Drug Development Priorities Important to Physicians: Spain
                  • HCV Drug Development Priorities Important to Physicians: United Kingdom
                  • HCV Drug Development Priorities That Physicians View as Important to Payers: EU5
                  • HCV Drug Development Priorities That Physicians View as Important to Payers: France
                  • HCV Drug Development Priorities That Physicians View as Important to Payers: Germany
                  • HCV Drug Development Priorities That Physicians View as Important to Payers: Italy
                  • HCV Drug Development Priorities That Physicians View as Important to Payers: Spain
                  • HCV Drug Development Priorities That Physicians View as Important to Payers: United Kingdom
                  • Factors Influencing Selection of New HCV Therapies: EU5
                  • Factors Influencing Selection of New HCV Therapies: France
                  • Factors Influencing Selection of New HCV Therapies: Germany
                  • Factors Influencing Selection of New HCV Therapies: Italy
                  • Factors Influencing Selection of New HCV Therapies: Spain
                  • Factors Influencing Selection of New HCV Therapies: United Kingdom
                  • Current and Anticipated Patient Share for Treatment-Naive Non-Cirrhotic Genotype 1 Patients
                  • Current and Anticipated Patient Share for Treatment-Naive Cirrhotic Genotype 1 Patients
                  • Current and Anticipated Patient Share for Treatment-Experienced Non-Cirrhotic Genotype 1 Patients
                  • Current and Anticipated Patient Share for Treatment-Experienced Cirrhotic Genotype 1 Patients
                  • Current and Anticipated Patient Share for Treatment-Naive Non-Cirrhotic Genotype 1 Patients, Split by Physician Specialty
                  • Current and Anticipated Patient Share for Treatment-Naive Cirrhotic Genotype 1 Patients, Split by Physician Specialty
                  • Current and Anticipated Patient Share for Treatment-Experienced Non-Cirrhotic Genotype 1 Patients, Split by Physician Specialty
                  • Current and Anticipated Patient Share for Treatment-Experienced Cirrhotic Genotype 1 Patients, Split by Physician Specialty
                  • Current and Anticipated Patient Share for Treatment-Naive Non-Cirrhotic Genotype 3 Patients
                  • Current and Anticipated Patient Share for Treatment-Naive Cirrhotic Genotype 3 Patients
                  • Current and Anticipated Patient Share for Treatment-Experienced Non-Cirrhotic Genotype 3 Patients
                  • Current and Anticipated Patient Share for Treatment-Experienced Cirrhotic Genotype 3 Patients
                  • Anticipated Prescribing of Sofosbuvir/Velpatasvir +/- RBV vs. Most Prescribed Current Regimen in Treatment-Naive Non-Cirrhotic Genotype 2 Patients
                  • Anticipated Prescribing of Sofosbuvir/Velpatasvir +/- RBV vs. Most Prescribed Current Regimen in Treatment-Naive Cirrhotic Genotype 2 Patients
                  • Anticipated Prescribing of Sofosbuvir/Velpatasvir +/- RBV vs. Most Prescribed Current Regimen in Treatment-Experienced Non-Cirrhotic Genotype 2 Patients
                  • Anticipated Prescribing of Sofosbuvir/Velpatasvir +/- RBV vs. Most Prescribed Current Regimen in Treatment-Experienced Cirrhotic Genotype 2 Patients
                  • Anticipated Prescribing of Sofosbuvir/Velpatasvir +/- RBV vs. Most Prescribed Current Regimen in Treatment-Naive Non-Cirrhotic Genotype 2 Patients, Split by Physician Specialty
                  • Anticipated Prescribing of Sofosbuvir/Velpatasvir +/- RBV vs. Most Prescribed Current Regimen in Treatment-Naive Cirrhotic Genotype 2 Patients, Split by Physician Specialty
                  • Anticipated Prescribing of Sofosbuvir/Velpatasvir +/- RBV vs. Most Prescribed Current Regimen in Treatment-Experienced Non-Cirrhotic Genotype 2 Patients, Split by Physician Specialty
                  • Anticipated Prescribing of Sofosbuvir/Velpatasvir +/- RBV vs. Most Prescribed Current Regimen in Treatment-Experienced Cirrhotic Genotype 2 Patients, Split by Physician Specialty
                  • Current and Anticipated Patient Share for Treatment-Naive Non-Cirrhotic Genotype 3 Patients, Split by Physician Specialty
                  • Current and Anticipated Patient Share for Treatment-Naive Cirrhotic Genotype 3 Patients, Split by Physician Specialty
                  • Current and Anticipated Patient Share for Treatment-Experienced Non-Cirrhotic Genotype 3 Patients, Split by Physician Specialty
                  • Current and Anticipated Patient Share for Treatment-Experienced Cirrhotic Genotype 3 Patients, Split by Physician Specialty
                  • HCV Regimens Most Likely to Be Displaced by Zepatier +/- RBV
                  • HCV Regimens Most Likely to Be Displaced by Sofosbuvir/Velpatasvir +/- RBV
                  • Reasons Why Zepatier +/- RBV Will Not Displace Any Currently Available HCV Regimen: EU5
                  • Reasons Why Zepatier +/- RBV Will Not Displace Any Currently Available HCV Regimen: France
                  • Reasons Why Zepatier +/- RBV Will Not Displace Any Currently Available HCV Regimen: Germany
                  • Reasons Why Zepatier +/- RBV Will Not Displace Any Currently Available HCV Regimen: Italy
                  • Reasons Why Zepatier +/- RBV Will Not Displace Any Currently Available HCV Regimen: Spain
                  • Reasons Why Zepatier +/- RBV Will Not Displace Any Currently Available HCV Regimen: United Kingdom
                  • Reasons Why Sofosbuvir/Velpatasvir +/- RBV Will Not Displace Any Currently Available HCV Regimen: EU5
                  • Reasons Why Sofosbuvir/Velpatasvir +/- RBV Will Not Displace Any Currently Available HCV Regimen: France
                  • Reasons Why Sofosbuvir/Velpatasvir +/- RBV Will Not Displace Any Currently Available HCV Regimen: Germany
                  • Reasons Why Sofosbuvir/Velpatasvir +/- RBV Will Not Displace Any Currently Available HCV Regimen: Italy
                  • Reasons Why Sofosbuvir/Velpatasvir +/- RBV Will Not Displace Any Currently Available HCV Regimen: Spain
                  • Reasons Why Sofosbuvir/Velpatasvir +/- RBV Will Not Displace Any Currently Available HCV Regimen: United Kingdom
                  • Physician Opinion on Zepatier Pricing Scenarios Required to Obtain Favorable Formulary Status
                  • Physician Opinion on Sofosbuvir/Velpatasvir Pricing Scenarios Required to Obtain Favorable Formulary Status
                  • EU5 Physician Opinion on Zepatier and Sofosbuvir/Velpatasvir Pricing Scenarios Required to Obtain Favorable Formulary Status
                  • Future HCV Patient Populations Prioritized for Treatment
                  • Future Market Potential and Likely Market Access Issues for Zepatier
                  • Future Market Potential and Likely Market Access Issues for Sofosbuvir/Velpatasvir
                  • Estimated Delay in Availability of HCV Regimens After EMA Approval
                  • French Physicians' Opinion of Whether Sofosbuvir/Velpatasvir Should Receive Temporary Authorization for Use (ATU)
                  • Anticipated IQWiG/G-BA Ratings for Emerging HCV Therapies
                  • Italian Physicians' Opinion of HCV Emerging Therapies' Potential to Receive Innovative Status
                  • Anticipated AEMPS Recommendations for Emerging HCV Therapies
                  • U.K. Physicians' Opinion of Anticipated Market Access Issues Facing Emerging HCV Therapies
                  • Current and Anticipated Impact of Regional Formulary Variation on Patient Access to HCV Therapies

            Author(s): James Heeres, PhD; Laurie J. Dimodica, MS

            James is a part of the infectious, niche markets, and rare diseases team at DRG. His work involves evaluating treatment landscape, unmet needs, emerging therapy positioning, commercial potential, drug development opportunities, and company competitiveness. Currently, his concentration is in hepatitis C virus (HCV) infection in US and EU5 markets.

            James earned his Ph.D. in biochemistry from the University of Illinois at Urbana-Champaign while studying high-throughput screening technologies and small-molecule inhibitors of apoptosis. Prior to joining DRG, his postdoctoral studies involved drug discovery and development in neurodegenerative diseases at both Harvard Medical School and Boston University School of Medicine.

            Laurie DiModica has more than two decades of experience in healthcare and biopharmaceutical market research in the major and emerging markets. She currently works on DRG’s Access & Reimbursement series (formerly European Physician and Payer Forum) and its Global Market Access Solutions product. Ms. DiModica was previously a Medical Publications and Conference Director for the Institute for International Research, specializing in the U.S. managed care market. She has an M.S. from Simmons College in Boston.